Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

MiR-75 as well as mimics and application thereof

A technology of miR-75 and mimics, applied in the field of miR-75 and its mimics and applications, can solve problems such as easy recurrence, limited long-term curative effect, and large adverse drug reactions, and achieve the effect of reducing inflammatory indicators

Pending Publication Date: 2022-07-01
GUANGZHOU UNIVERSITY OF CHINESE MEDICINE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Clinically, the adverse reactions of the drugs are large, and the recurrence is easy after drug withdrawal, and the long-term efficacy is limited.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • MiR-75 as well as mimics and application thereof
  • MiR-75 as well as mimics and application thereof
  • MiR-75 as well as mimics and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] 1. Experimental materials

[0038] 1.1 Experimental animals

[0039] Healthy SPF grade C57BL / 6 mice, 8-10 weeks old, weighing 22-25 g, were provided by the Experimental Animal Center of Guangzhou University of Traditional Chinese Medicine. Animal license number: SCXK (Beijing) 2019-0010.

[0040] 1.2 Reagents

[0041] The nucleotide sequence of miR-75 is:

[0042] 5'-GGGGGACGGGGCGGGUGC-3' (SEQ ID NO. 1);

[0043] The nucleotide sequence of the mimetic of miR-75 is:

[0044] 5’-GGGGGACGGGGCGGGUGC-3’

[0045] 5'-ACCCGCCCCGUCCCCCUU-3' (SEQ ID NO. 2). like figure 1 shown.

[0046] Sodium monourate crystal (MSU) was purchased from InvivoGen, USA; the mimic of miR-75 was derived from the brain substantia nigra of SD rats (provided by the Experimental Animal Center of Guangzhou University of Traditional Chinese Medicine). Its precursor sequence and mature body sequence were compared with miRNA databases such as miRBase, StarBase, miRecords, and miRTarBase, and no miRN...

Embodiment 2

[0072] 1. The miR-75 mimic powder chemically synthesized according to the nucleotide sequence of the miR-75 mimic by Suzhou Gema Gene Co., Ltd. will be prepared for injection by the preparation method of medicinal injection. Specifically, 500 mg of the miR-75 mimic was dissolved in a mixture of 20 mL of 1,2 propylene glycol and 2 mL of Tween-80, and water for injection was added to 250 mL. After mixing evenly, pour it into a bottle, seal it, and sterilize it to make a 2mg / mL injection. This product is used for intravenous injection (iv.), 1 per day for adults, that is, 2 mg / day; the usual dose for children: 0.05 mg / kg / day according to body weight.

[0073] 2. The miR-75 mimic powder chemically synthesized by Suzhou Gema Gene Co., Ltd. according to the nucleotide sequence of the miR-75 mimic was prepared into capsules by the preparation method of medicinal capsules. Specifically: 25000 mg of miR-75 mimic, 4500 mg of calcium carbonate, 500 mg of starch, mixed uniformly to make ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses miR-75 as well as mimics and application thereof, and belongs to the field of disease gene therapy. The invention provides miR-75 with a nucleotide sequence as shown in SEQ ID NO.1. The miR-75 is used as a novel miRNA, and a mimic of the miR-75 has a certain prevention effect on gouty arthritis, so that a novel target is provided for drug treatment of the gouty arthritis. The miR-75 simulant is a small-fragment single-chain RNA (Ribonucleic Acid) designed and synthesized aiming at the nucleotide sequence of the miR-75, and the sequence of the small-fragment single-chain RNA is reversely complementary with the nucleotide sequence of the miR-75. The miR-75 simulant can reduce the inflammatory response of gouty arthritis by reducing the expression level of interleukin-1 beta protein, so that joint swelling is relieved, and the miR-75 simulant has huge application potential in the aspects of prevention and treatment of gouty arthritis.

Description

technical field [0001] The invention belongs to the field of disease gene therapy, and in particular relates to a miR-75 and its mimics and applications. Background technique [0002] Gouty arthritis is a common clinical metabolic disease. Due to the abnormal excretion or production of uric acid, the final metabolite of purine, a large amount of urate is deposited in the joint capsule cavity, synovial sac, cartilage, bone and other tissues, causing an arthritic reaction. , with joint redness, swelling, heat, pain, and movement disorders as the main clinical manifestations. Clinically, the treatment drugs have serious adverse reactions, and are prone to relapse after drug withdrawal, and the long-term efficacy is limited. [0003] MicroRNA (micro RNA, miRNA for short) is a kind of short-sequence, non-coding, single-stranded small molecule RNA with regulatory functions, about 18-25 nt in length. miRNAs have diverse biological functions and are currently thought to be involve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/113A61K31/7088A61K45/00A61P19/06A61P19/02A61P29/00
CPCC12N15/113A61K31/7088A61K45/00A61P19/06A61P19/02A61P29/00
Inventor 陈东风刘爱军翁安莉骆紫薇窦健萍
Owner GUANGZHOU UNIVERSITY OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com